As one of the few men attending the RSM's conference on domestic violence with Dr Golding, I have no quarrel with his summary of what was presented by the speakers (June 2002 JRSM 1 ). The point where I differ with what he has presented concerns the things that were not said but needed to be said at this meeting.
Anyone attending this conference fresh to the subject of domestic violence would have left with the belief that this age-old phenomenon was almost exclusively what men do to women and children. In the western world today, nothing could be further from the truth. There is a large body of work documenting violence in the domestic scene by women against men and children. In many studies the incidence is at, or close to, parity. The data come from the USA, Canada, New Zealand and Australia in addition to the UK. When this fact was raised from the floor during discussion, it was described as 'polarizing the argument' and the remarkable idea that 'women are only violent in response to violence from men'. Fortunately a keynote speaker, Dame Elizabeth Butler-Sloss, had referred to the unpalatable fact of female-perpetrated violence in the home. She also drew the conference's attention to the unmeasured volume of psychological abuse perpetrated by both sexes in the domestic environment, equally if not more damaging to the child.
Domestic violence deserves to be considered in a more balanced way at subsequent meetings on the subject.
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Immunotherapy for cancer
Dr Grange and colleagues conclude that recent advances in the understanding of the nature of the immune response will enable a move 'from the empirical to the rational approach' in devising immunotherapy for cancer (June 2002 JRSM 1 ). They quote latent periods in the progress of cancer and of tuberculosis as evidence that an immune response is involved in both cases. This need not be so.
In both diseases there is cell death in the centre of masses (whether tubercles or cancers) that have outstripped their circulation 2 . In cancers the dead tissue may become organized and potentially proliferative cells sequestered, remote from blood-borne treatment and resistant to radiation through hypoxia. Successful treatment of the outer well-vascularized tumour leaves a core that may be slowly resorbed until the sequestered cells are exposed to a fresh blood supply; regrowth then occurs.
In the interpretation of so-called latent periods in cancer the most influential factor is a huge range of growth rates. In our series of unselected breast cancers 3 the 95% confidence intervals of the distribution of inferred volume doubling times were 6 and 121 days. Some 30 doublings of volume from a single cell are required to produce a clinically detectable tumour of about 1 cm in diameter. Thus growth from a single cell might take more than 10 years to achieve a diagnosable size. The published work abounds with much more slowly growing examples 4 . After treatments, any residual subclinical disease is unmeasurable over a range of sizes that represent three-quarters of the life-span of a tumour.
One may not assume that apparent delays in growth result from an immune response. Chronic subdural haematoma in the elderly In the series reported by Dr Asghar and colleagues (June 2002 JRSM 1 ) one-third of the subdural haematomas were in patients receiving antithrombotic therapy. It is a perverse paradox that thromboprophylaxis of age-related disorders such as atrial fibrillation and coronary thrombosis happens to be one of the most significant risk factors for subdural haematoma. Profiling of anticoagulant-related haemorrhagic risk might be of use in identifying those patients for whom alternative strategies, such as cardioversion to sinus rhythm (including drug treatment to prevent relapse), might be preferable for managing embolic risk in disorders such as atrial fibrillation. Profiling for CYP2C0 genetic variants shows promise, in this respect, with documentation of a significant association between warfarin-related haemorrhagic risk (including risk of life-threatening bleeding episodes) and either CYP2C9#2 or CYP2C9#3 polymorphism 2 , the hepatic microsomal enzyme CYP2C9 being the primary pathway for the metabolism of s-warfarin. For identification of risk of warfarin-related cerebral haemorrhage there is already evidence that there is an important V o l u m e 9 5 A u g u s t 2 0 0 2
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